A prospective multicenter DAHANCA study of hyperfractionated accelerated RT for head and neck cancer

Saksø, M.; Andersen, E.; Bentzen, J.; Andersen, M.; Johansen, J.; Overgaard, J; Eriksen, J.G.

Published in:
Radiotherapy & Oncology

DOI (link to publication from Publisher):
10.1016/S0167-8140(19)30808-4

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):
OC-0387 radiotherapy with paclitaxel/cisplatin vs. fluorouracil/cisplatin for head and neck cancer
R. Fietkau1, M. Hecht1, B. Hofner2, H. Iro3, O. Gefeller2, Schleswig-Holstein- Lübeck, Department of Radiotherapy, Mönchengladbach, Germany ; 10University Maria Hilf- Mönchengladbach, Department of Oncology, Düsseldorf, Germany ; 11University of Hospital of Düsseldorf, Department of Radiation Oncology, Frankfurt, Germany ; 5University Hospital of Hospital Frankfurt, Department of Radiotherapy and Biometrie und Epidemiologie IMBE, Erlangen, Germany ; 12Klinik am Eichert- Göppingen, Department of Radiotherapy, Göppingen, Germany ; 13Coburg Cancer Center, Department of Radiation Oncology, Coburg, Germany ; 14University Hospital Zurich, Department of Radiation Oncology, Zurich, Switzerland

Purpose or Objective
The utilization of taxanes has demonstrated promising results in squamous cell carcinoma of the head and neck (SCCHN) as induction chemotherapy prior to definitive chemoradiotherapy (CRT). The purpose of this multicenter, phase 3 trial was to investigate whether the incorporation of concurrent paclitaxel and cisplatin together with a slightly reduced total dose of radiotherapy (RT) is superior compared with standard fluorouracil-cisplatin based CRT.

Material and Methods
Previously untreated patients with non-metastatic SCCHN, stage III-IVB, were randomized to receive paclitaxel/cisplatin(PacCis)-CRT (arm A; paclitaxel 20 mg/m² on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 mg/m², days 1-4 and 29-32; RT to a total dose of 63.6 Gy) or fluorouracil/cisplatin(CisFU) -CRT (arm B; fluorouracil 600 mg/m² ; cisplatin 20 mg/m², days 1-5 and 29-33; RT: 70.6 Gy). Primary endpoint was 3-year-disease free survival (3y-DFS). Secondary endpoints included overall survival (OS), locoregional failure rate (LFR), distant failure rate (DFR), and toxicity.

Results
A total of 221 patients have been enrolled in 14 sites between 2010 and 2015. With a median follow-up of 3.7 years, 3y-DFS in the CisFU arm and PacCis arm was 58.2% and 48.4%, respectively (HR 0.82, 95% CI 0.56-1.21, p=0.52). The 3y-OS amounted to 64.6% in the CisFU arm, and to 59.2% in the PacCis arm (HR 0.82, 95% CI 0.54-1.21, p=0.43). There were no significant differences for LFR and DFR. In the subgroup of p16-positive oropharyngeal carcinomas, 3y-DFS and 3y-OS was 84.6% vs 83.9% (p=0.653), and 92.3% vs. 83.5% (p=0.76) in arm A and B, respectively. Hematological toxicities grade 3-4 were significantly reduced in arm A (anemia, p=0.01; leukocytopenia, p =0.003).

Conclusion
Paclitaxel/cisplatin-CRT with a slightly reduced total RT-dose is not superior to standard fluorouracil/cisplatin-CRT. Subgroup analyses indicate that a reduced radiation dose seems to be sufficient for p16+ oropharyngeal cancer and/or in non-smokers.

OC-0388 A prospective multicenter DAHANCA study of hyperfractionated accelerated RT for head and neck cancer
M. Saksø1, E. Andersen2, J. Bentzen2, M. Andersen3, J. Johansen4, J. Overgaard1, J.G. Eriksen1
1Aarhus University Hospital, Dept. of Experimental Clinical Oncology, Aarhus, Denmark ; 2Herlev Hospital, Dept. of Oncology, Herlev, Denmark ; 3Aalborg University Hospital, Dept. of Oncology, Aalborg, Denmark ; 4Odense University Hospital, Dept. of Oncology, Odense, Denmark

Conclusion
Paclitaxel-cisplatin-CRT with a slightly reduced total RT-dose is not superior to standard fluorouracil-cisplatin-CRT. Subgroup analyses indicate that a reduced radiation dose seems to be sufficient for p16+ oropharyngeal cancer and/or in non-smokers.
Purpose or Objective

The DAHANCA9 hyperfractionation study and the MARCH meta-analysis (Bourhis et al, Lancet 2006) on altered fractionation showed that Hyperfractionated Accelerated Radiotherapy (HART) is superior in terms of loco-regional control (LRC) and overall survival (OS) compared to conventional or moderately accelerated radiotherapy for Head and Neck Squamous Cell Carcinomas (HNSCC). Since 2007, HART has been included as a treatment option in the Danish HART radiotherapy guidelines. The aim of the present study was to evaluate this treatment strategy using LRC, OS and late morbidity as endpoints.

Material and Methods

Prospectively registered patients (pts) with HNSCC treated with HART according to national guidelines prescribed as 76Gy/56fx, 10 fx/week, as primary treatment were identified in the DAHANCA database and updated. The study was evaluated as intention to treat and elective neck-dissection was not an option.

Results

From July 2007 to December 2017, 271 pts with HNSCC treated with HART were identified in four national cancer centers that on a regular basis offers HART according to treatment guidelines. The median age was 64 years (32-81 years) and 50% were males. The majority of the cases were stage III-IV (UICC7). In the pharynx, 138 cases (76%) were of oropharyngeal origin and of those, 48% were HPV-positive. The proportion of pts receiving HART as planned was 96%. No patients received adjuvant or concomitant chemotherapy. As per September 1st 2018, 50 loco-regional failures (19% of the pts) were detected with a median follow-up time of 29 months: 47 occurred in T-site and 15 in N-site. Among those, 12 pts had both T- and N-site failure. Three-year actuarial LRC was 81% and OS was 68%. LRC at three years was significantly different for stage I-II and stage III-IV HNSSC (90% vs. 74%, HR 0.44 (range 0.23-0.81)) but not significantly better for HPV-positive oropharyngeal carcinomas compared to the HPV-negative oropharynx pts (94% vs 89%). The proportion of pts reporting severe late dysphagia was 16%, and 9% reported late, severe dryness of the mouth; 8% were observed with late edema in the larynx, 16% with severe mucosal atrophy and 5% with severe fibrosis of the subcutaneous tissue in the neck region.

Conclusion

Hyperfractionated accelerated radiotherapy is an attractive treatment approach in patients with HNSSC. Three-year loco-regional control as observed in this study is more than 80% and that is reflected in an acceptable overall survival. In this study, HART produced equally good results for HPV-positive and HPV-negative oropharyngeal cancer patients. Severe late morbidity is reasonably low and comparable to treatment with chemo-radiotherapy.

OC-0389 Individualized prophylactic irradiation based on sentinel lymph node(s) identification in cNO HNSSC patients, prophylactic and often bilateral neck irradiation is mandatory. However, it leads to a large irradiation of healthy tissues and could miss unexpected nodal basins drained by the tumor. This prospective, non-randomized, intervention phase II study investigated how sentinel lymph node (SLN) mapping by SPECT/CT might help to individualize prophylactic neck irradiation and its potential impact on radiation-related toxicities and tumor control. The final results are presented.

Material and Methods

Forty-four patients with newly diagnosed cNO squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx were included and treated with upfront (chemo)radiotherapy with a curative intent. After simulation, all patients were imaged in treatment position with SPECT/CT after Tc-99m nanocolloid injection around the tumor. The neck levels containing up to four hottest SLN were selected for prophylactic irradiation (CTVn-LS).

A comparative virtual planning was performed by including the levels selected on the basis of the current international guidelines (CTVn-IG). Dosimetric data to the different organs-at-risk (OAR) were compared between both plans. Normal tissue complication probability (NTCP) models for xerostomia and dysphagia as well as quality of life assessments (EORTC C30 and HEN33 scales) are being investigated to predict the clinical benefit of this technique.

Results

Lymphatic migration was observed in all of the 44 patients. Four patients (9%) presented an unpredicted lymphatic drainage and 21 patients (48%) had only an unilateral drainage. The volumes of CTVn-LS and CTVn-IG (median volumes of 91.8 cc and 219.1 cc, respectively) were systematically smaller than CTVn-IG and PTv-IG (median volumes of 188.3 cc and 405.3 cc, respectively). This led to a significant dose decrease in identified OAR, particularly to the contralateral parotid gland, contralateral submandibular gland, inferior constrictor muscle for oropharynx tumors and superior constrictor muscle for larynx/hypopharynx tumors (Table 1). NTCP values and QoL data processing is still work in progress and will be presented during the congress. At a median follow-up of 42 months, 3 patients experienced a regional relapse: 2 in an irradiated area (4.5%) and 1 in a non-irradiated area (2.3%). Currently, 4 patients had a local recurrance and 6 patients died (2 patients from geriatric degradation and 4 patients experienced fatal local relapse).

Conclusion

SLN mapping using SPECT/CT allowed to significantly reduce the prophylactically irradiated neck volumes in cNO HNSSC patients. This resulted in a significant dose decrease in OAR, especially in patients presenting an unilateral lymphatic drainage, while uncompromising the...